Key result
Single-dose CER-001 matches placebo safety and mobilizes HDL cholesterol starting at /kg.
RCT (n=32)
Double-blind
Randomized cross-over
Answers are grounded in this paper and cite their sources.
BACKGROUND: CER-001 comprises recombinant human apolipoprotein A-I complexed with phospholipids that mimics natural, nascent, pre-β high-density lipoprotein (HDL). We present animal model data showing dose-dependent increases in cholesterol efflux with CER-001 and its subsequent elimination by reverse lipid transport, together with inhibition of atherosclerotic plaque progression. We report the first phase I study results with CER-001 in humans, starting at 0.25 mg/kg, which is 1/80th of the safe dose (20 mg/kg) established in 4-week multiple-dose animal studies dosed every second day. METHODS: Healthy volunteers, 18-55 years old with a low-density lipoprotein-cholesterol:HDL-cholesterol ratio greater than 3.0, received single intravenous escalating doses of CER-001 (0.25-45.0 mg/kg) and placebo in a double-blind randomised cross-over fashion. Subjects were followed up for 3 weeks post-dose. Assessments included adverse event monitoring, blood sampling, and clinical laboratory measurements. RESULTS: Thirty-two subjects were enrolled. All CER-001 doses (0.25-45 mg/kg) were safe and well tolerated, with an adverse event profile similar to placebo. Effects on clinical chemistry, haematology and coagulation parameters were comparable to placebo. No adverse effects of CER-001 on electrocardiograms were observed. No antibodies to apolipoprotein A-I were detected following single-dose administration of CER-001. Plasma apolipoprotein A-I levels increased in a dose-related manner and returned to baseline by 24 h post-dose for doses up to 10 mg/kg but remained in circulation for >72 h post-dose for doses >10 mg/kg. CER-001 caused elevations in plasma cholesterol and total and unesterified cholesterol in the HDL fraction. Mobilisation of unesterified cholesterol in the HDL fraction was seen with CER-001 at doses as low as 2 mg/kg. CONCLUSION: CER-001 is well tolerated when administered to humans as single doses up to 45 mg/kg and mobilises and eliminates cholesterol via reverse lipid transport.
No takes yet. Share an insight, caveat, or question.
Keyserling et al. (2017) conducted an RCT in Healthy volunteers with elevated LDL-C:HDL-C ratio (n=32). CER-001 (recombinant human apolipoprotein A-I complexed with phospholipids) vs. Placebo was evaluated on Safety, tolerability, pharmacokinetics, and cholesterol mobilization. Single intravenous doses of CER-001 were well tolerated with an adverse event profile similar to placebo and mobilized unesterified HDL cholesterol at doses as low as /kg.
Synapse has enriched 10 related papers. Consider them for comparative context: